Skip to main content
. 2026 Apr 5;16:16338. doi: 10.1038/s41598-026-46649-w

Table 2.

Cox proportional hazards analysis of risk factors associated with cancer-specific mortality in patients with cTa and cT1 bladder cancer based on the complete case dataset.

Variable Univariable analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Age (per 10 year increase) 1.61 (1.04–2.48) 0.032 1.73 (1.09–2.74) 0.022
Sex, male vs. female 1.06 (0.41–2.72) 0.9
ECOG-PS, >=2 vs. 0–1 3.88 (1.18–12.73) 0.025 2.10 (0.61–7.56) 0.3
Smoking history 0.79 (0.37–1.66) 0.5
History of NMIBC 1.32 (0.68–2.54) 0.4
History of BCG 0.58 (0.25–1.33) 0.2
Tumour multiplicity, multiple vs. solitary 2.06 (0.80–5.34) 0.1
Size of tumours, >=3 cm vs. <3 cm 1.52 (0.75–3.07) 0.2
Clinical T stage, cT1 vs. cTa 3.28 (0.79–13.62) 0.1 4.48 (1.11–20.40) 0.043
Concomitant CIS (TUR and/or RC) 0.74 (0.39–1.42) 0.4
NAC, >=2 cylcles vs. 0–1 cycle 1.18 (0.49–2.84) 0.7 2.44 (0.85–5.56) 0.066
Calendar year of RC (per 1 year increase) 0.74 (0.60–0.91) 0.004 0.81 (0.61–0.92) 0.064
Surgical technique
Laparoscopic vs. open 0.42 (0.18–1.02) 0.054 0.48 (0.15–0.90) 0.1
Robotic vs. open 0.22 (0.03–1.59) 0.1 0.40 (0.03–1.69) 0.4
LND, standard/extended vs. none/limited 0.66 (0.29–1.50) 0.3
Upstaging to > = pT2 or pN+ disease 9.00 (4.35–18.63) < 0.001 6.53 (3.02–14.81) < 0.001
Histological subtype (TUR and/or RC) 1.01 (0.44–2.54) 0.9
Adjuvant chemotherapy 4.25 (2.06–8.79) < 0.001 1.97 (0.91–4.92) 0.12

Significant values are in bold.